HITCHIPDIAG
Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0HITCHIPDIAG project word cloud
Explore the words cloud of the HITCHIPDIAG project. It provides you a very rough idea of what is the project "HITCHIPDIAG" about.
Project "HITCHIPDIAG" data sheet
The following table provides information about the project.
| Coordinator |
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 147˙094 € |
| EC max contribution | 147˙094 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2014-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-04-01 to 2016-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV | DE (MUENCHEN) | coordinator | 147˙094.00 |
Map
Project objective
Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans Heparin, a complex glycosaminoglycan (GAG) carbohydrate, is the most commonly used anticoagulant. Twelve million patients in the EU are treated annually for conditions including acute coronary syndrome, deep-vein thrombosis and cardiopulmonary bypass surgery. Heparin-induced thrombocytopenia (HIT) is a dangerous adverse side effect of heparin administration. HIT-II develops after major surgery or dialysis and results in infarction, multi-organ failure and 20% mortality. In Europe 100,000 patients develop HIT-II annually. Currently, two HIT-II diagnostics are available. The HIPA and MAIPA tests detect antibodies against a complex of heparin and platelet factor 4 but suffer from low diagnostic specificity and accuracy. Faster, more reliable and cheaper methods to diagnose complications after administration of heparin are needed to improve patient wellbeing and reduce costs. The ERC Advanced grant AUTOHEPARIN yielded an instrument for the automated assembly of defined oligosaccharides. GAG glycan microarrays were produced by printing GAG oligosaccharides onto surfaces and used to screen patient blood. Specific glycan markers of high diagnostic value were discovered to detected HIT-II within minutes and reliabilities well above existing tests. The overall goal of the project is to establish the business model for a company that will focus on the production of GAG glycan arrays as HIT diagnostic. Specific activities include: 1) Development of standard protocols to detect HIT-II using GAG glycan microarray; 2) Plan and cost structure for GAG arrays production; 3) Analysis of the IP space and development of an IP strategy; 4) Evaluate potential markets and establish basis for commercial discussion with potential customers; 5) Prepare business plan for discussions with investors; 6) Incorporate company to commercialize GAG arrays as HIT diagnostic
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HITCHIPDIAG" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HITCHIPDIAG" are provided by the European Opendata Portal: CORDIS opendata.